Multiple Myeloma

Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.

Current unmet needs surrounding the management of patients with triple-class refractory multiple myeloma with newer novel therapies.

Guidance regarding proper treatment selection and sequencing of therapies for triple-class refractory multiple myeloma.

Monalisa Ghosh, MD, discusses the impact of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Matthew James Pianko, MD, discusses the role of daratumumab in the frontline treatment of multiple myeloma.

Silver linings of the COVID-19 pandemic have opened the door for new opportunities for decentralized clinical trials and real-world data in a post–COVID-19 world.

An overview of the DREAMM-2 study of belantamab mafodotin for triple-class refractory patients with multiple myeloma, with special considerations for managing treatment-related corneal events.

The rationale for adding melflufen to dexamethasone as treatment for patients with triple-class refractory multiple myeloma.

UCARTCS1A demonstrated early antitumor activity in heavily pretreated patients with relapsed/refractory multiple myeloma in whom previous CAR T-cell therapy and/or transplant had failed, according to preliminary data from the phase 1 MELANI-01 trial.

Novel combinations are paramount for patients with relapsed/refractory multiple myeloma who are in second relapse or beyond; some isatuximab-irfc–containing regimens have the potential to move to the frontline setting and combining melphalan flufenamide with proteasome inhibitors and anti-CD38 monoclonal antibodies is an active area of interest.

Ola Landgren, MD, PhD, discusses the clinical impact of the 4-drug combination of carfilzomib, lenalidomide, dexamethasone, and daratumumab in patients with multiple myeloma.

Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.

Nikhil C. Munshi, MD, discusses how idecabtagene vicleucel has potentially marked the beginning of a new chapter for cellular therapy in multiple myeloma.

Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.

The treatment paradigm for relapsed/refractory multiple myeloma has expanded rapidly with the recent integration of selinexor and BCMA-directed therapies, such as belantamab mafodotin-blmf and idecabtagene vicleucel.

The quadruplet combination comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab was linked with high rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma.

Nicolaus Kröger, MD, discusses toxicities associated with allogeneic stem cell transplant in patients with multiple myeloma.

Luciano J. Costa, MD, PhD, shares key updates regarding transplanteligible and -ineligible patients with multiple myeloma, novel triplet and quadruplet regimens that are shifting standards in the frontline setting, and other modalities under active exploration.

Considerations for adding selinexor to backbone treatments for triple-class refractory multiple myeloma based on data revealed by the STOMP trial.

Insight regarding the risk of development of triple-class refractory disease in multiple myeloma and recommendations for working with patients to establish an appropriate treatment plan and counsel on goals of therapy.

Dickran G. Kazandjian, MD, discusses novel therapeutic targets in multiple myeloma.

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

Daratumumab plus lenalidomide and dexamethasone, or plus bortezomib and dexamethasone each led to higher rates of minimal residual disease negativity compared with lenalidomide plus dexamethasone or bortezomib plus dexamethasone alone in patients with relapsed/refractory multiple myeloma who were enrolled in the phase 3 POLLUX and CASTOR trials, translating to prolonged, durable remissions.

Benjamin Diamond, MD, discusses the rationale for examining long-term minimal residual disease in patients with multiple myeloma.

New triplet combinations anchored by anti-CD38 antibodies are expanding the therapeutic landscape for relapsed or refractory multiple myeloma, providing exciting options that extend progression-free survival windows from months to years for heavily pretreated patients.

The addition of motixafortide to granulocyte colony stimulating factor resulted in a 4.9-fold increase in achieving target stem-cell mobilization for autologous bone marrow transplantation in up to 2 apheresis sessions vs G-CSF alone in patients with multiple myeloma, meeting the primary end point of the phase 3 GENESIS trial.

Nearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.

Strategies for patient assessment and treatment selection in patients with relapsed/refractory multiple myeloma.